<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00205231</url>
  </required_header>
  <id_info>
    <org_study_id>2001-557</org_study_id>
    <nct_id>NCT00205231</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease</brief_title>
  <official_title>A Pilot Study to Examine the Feasibility and Effect on Tumor Necrosis Factor (TNF) Inhibition on HIV Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunex Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <brief_summary>
    <textblock>
      This pilot study will investigate the safety and effect of etanercept in HIV infection by
      studying HIV replication and immune function (as measured by CD4 counts) in individuals with
      HIV infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in CD4 counts</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in HIV-RNA levels</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>development of infections</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>degree of TNF inhibition by measuring TNF levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in hematologic and biochemical laboratory tests</measure>
  </secondary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults greater than 18 years of age with documented HIV infection

          -  Highly active antiretroviral therapy (HAART) regimens as defined by the Department of
             Health and Human Services guidelines; stable regimens for 12 weeks.

          -  CD4 greater than 200 at time of study enrollment

          -  Stable monitoring labs (hematology survey with differential, ALT, creatinine)

          -  Absolute neutrophil count within normal limits

        Exclusion Criteria:

          -  AIDS defining illness within the last 6 months

          -  Acute bacterial, viral, or fungal infection within the last 1 month, or history of
             recurring infections

          -  Women who are pregnant or nursing

          -  Hypersensitivity to etanercept

          -  Previous use of etanercept

          -  Acute malignancy in the last 5 years excluding in situ cervical cancer (CA) and common
             skin cancers (non melanoma)

          -  History of active or latent tuberculosis

          -  History of demyelinating nerve disease

          -  History of seizure disorder

          -  Latex allergy

          -  Subject has any of the following laboratory values within 30 days of baseline:

               -  hemoglobin concentration &lt; 10.0 g/dl for men and &lt; 9.0 g/dl for women

               -  platelet count &lt; 75,000/mm3

               -  AST or ALT &gt; 5x upper limit of normal (ULN)

               -  serum creatinine &gt; 2.5x ULN

               -  serum pancreatic amylase &gt; 1.5 ULN

          -  Subject requiring treatment with immunomodulating agents, such as systemic
             corticosteroids, interleukins, vaccines, or interferon

          -  Subjects who chronically use any over-the-counter (OTC) or prescription medication
             (except vitamins) must not change the regimen or switch their medication within 3 days
             of drug administration and until discharged from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Urban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

